Kathleen Sebelius insider trades
Open-market stock purchases and sales by Kathleen Sebelius, Director at Humacyte, Inc, from SEC Form 4 filings since Sep 30, 2015.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +28%.
Open-market stock purchases and sales by Kathleen Sebelius, Director at Humacyte, Inc, from SEC Form 4 filings since Sep 30, 2015.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +28%.